TROKENDI XR: payments to doctors
Payments that named TROKENDI XR as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 10,308
- Transactions
- 65,164
- Average per transaction
- $16
The per-transaction average — $16 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10,308 providers the average total is $101, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | $1,039,984 | 100.0% |